Inicio>>Signaling Pathways>> Others>>BPK-29 hydrochloride

BPK-29 hydrochloride

Catalog No.GC38643

El clorhidrato de BPK-29 es un ligando especÍfico que interrumpe las interacciones de la proteÍna NR0B1 del receptor nuclear huérfano atÍpico (como RBM45 y SNW1) mediante la modificaciÓn covalente de C274. El clorhidrato de BPK-29 afecta el crecimiento independiente del anclaje de las células cancerosas mutantes en KEAP1.

Products are for research use only. Not for human use. We do not sell to patients.

BPK-29 hydrochloride Chemical Structure

Cas No.: 2444815-73-8

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
78,00 $
Disponible
5mg
70,00 $
Disponible
10mg
108,00 $
Disponible
50mg
432,00 $
Disponible
100mg
738,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BPK-29 hydrochloride is a specific ligand that disrupts the atypical orphan nuclear receptor NR0B1-protein (such RBM45 and SNW1) interactions by covalently modifying C274. BPK-29 hydrochloride impairs the anchorage-independent growth of KEAP1-mutant cancer cells[1].

BPK-29 hydrochloride substantially engages NR0B1 with good overall proteomic selectivity in KEAP1-mutant Non-Small Cell Lung Cancers[1].

[1]. Bar-Peled L, et al. Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer. Cell. 2017 Oct 19;171(3):696-709.e23.

Reseñas

Review for BPK-29 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BPK-29 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.